| scholarly article | Q13442814 |
| P2093 | author name string | Anita Rajasekhar | |
| Molly W Mandernach | |||
| Rebecca J Beyth | |||
| P2860 | cites work | Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. | Q50909355 |
| "Resistance" to warfarin due to unrecognized vitamin K supplementation. | Q54550134 | ||
| Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin | Q57243326 | ||
| Surgery and invasive procedures in patients on long-term treatment with direct oral anticoagulants: Thrombin or factor-Xa inhibitors. Recommendations of the Working Group on perioperative haemostasis and the French Study Group on thrombosis and haemo | Q61835374 | ||
| Dietary vitamin K1 and stability of oral anticoagulation: proposal of a diet with constant vitamin K1 content | Q73145805 | ||
| Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients | Q81670366 | ||
| Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials | Q85185536 | ||
| Apixaban for extended treatment of venous thromboembolism | Q85631280 | ||
| Use of PER977 to reverse the anticoagulant effect of edoxaban | Q85912324 | ||
| A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention | Q87233480 | ||
| Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24632872 | ||
| Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633010 | ||
| Apixaban versus warfarin in patients with atrial fibrillation | Q29617563 | ||
| Apixaban or enoxaparin for thromboprophylaxis after knee replacement | Q34018819 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial | Q34102430 | ||
| Risk assessment for recurrent venous thrombosis | Q34153343 | ||
| Apixaban versus enoxaparin for thromboprophylaxis after hip replacement | Q34156023 | ||
| Apixaban in patients with atrial fibrillation | Q34163710 | ||
| Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects | Q34285711 | ||
| A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa | Q34330708 | ||
| Oral anticoagulant therapies: balancing the risks | Q34342679 | ||
| Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents | Q34667503 | ||
| Vitamin K deficiency from dietary vitamin K restriction in humans | Q34687512 | ||
| Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development | Q34900298 | ||
| Economic burden of venous thromboembolism in hospitalized patients | Q34994523 | ||
| New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials | Q35160888 | ||
| Meta-analysis on risk of bleeding with apixaban in patients with renal impairment | Q35531302 | ||
| A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists | Q35535474 | ||
| Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752584 | ||
| New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q35752611 | ||
| Post-thrombotic syndrome: prevalence, prognostication and need for progress | Q37394831 | ||
| How I treat anticoagulated patients undergoing an elective procedure or surgery | Q38038988 | ||
| Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? | Q38197124 | ||
| Interactions of warfarin with drugs and food | Q38571033 | ||
| Oral apixaban for the treatment of acute venous thromboembolism | Q43741993 | ||
| Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). | Q44766243 | ||
| Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies | Q46722053 | ||
| A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer | Q48031013 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| apixaban | Q414462 | ||
| deep vein thrombosis | Q1762339 | ||
| P304 | page(s) | 1273-82 | |
| P577 | publication date | 2015-01-01 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review | |
| P478 | volume | 11 |
| Q55236233 | Comparison of apixaban and rivaroxaban for anticoagulant effect after lumbar spine surgery: a single-center report. |
| Q51462656 | Cost Effectiveness of Apixaban and Enoxaparin for the Prevention of Venous Thromboembolism After Total Knee Replacement in China. |
| Q41500949 | Left atrium mass in a patient with breast cancer: a case report |
| Q39458237 | Quick reference guide to apixaban |
| Q88708758 | Reduced dose apixaban resolving dual cardiac chamber thrombi in a patient with ischaemic cardiomyopathy in sinus rhythm |
| Q50955231 | [Monitoring of NOAC]. |
Search more.